Skip to main content

The professor of neurology at the University of Pennsylvania Perelman School of Medicine provided clinical insight on a long-term safety analysis of omaveloxlone, the first FDA-approved treatment for Freidreich ataxia. [WATCH TIME: 4 minutes]:

Source: Neurology Read More